Braeburn raises $110m for opioid use disorder depot injection

▤ Summary

Braeburn has raised $110 million to support its opioid use disorder depot injection program. The news points to continued investment in a pharmaceutical treatment platform rather than a software product announcement. The article text available here is minimal, so the core takeaway comes from the headline. This is relevant to pharma-focused software and life sciences vendors because funding can signal downstream needs in clinical, regulatory, manufacturing, or commercial systems.

$ Funding

▦ Linked Companies